News | June 07, 2022
NewAmsterdam Pharma shares new data from Phase 2b ROSE Study
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The Innovation Explorer database of GlobalData’s Disruptor Intelligence Center highlights how blockchain ensures the authenticity of products thereby, improves trust, traceability, and transparency across key sectors
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
This Keytruda combination is the first immunotherapy option approved in the EU for high-risk early-stage TNBC
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Belmore, the brand name of Bempedoic acid, is a novel drug for the treatment of high LDL-cholesterol.
Subscribe To Our Newsletter & Stay Updated
